GPX4 and gastric cancer: Dysregulation of GPX4 expression can lead to resistance to multiple therapeutic strategies, such as etoposide in NSCLC [35], 5‐fluorouracil (5‐FU) in gastric cancer [36, 37], tamoxifen in breast cancer [97] and TKIs in leukemia [38].